Hugli T E, Marceau F
Br J Pharmacol. 1985 Mar;84(3):725-33. doi: 10.1111/j.1476-5381.1985.tb16155.x.
Strips of rabbit blood vessels were suspended in vitro and responses to complement peptides C3a and C5a were recorded isotonically. Human C3a (up to 1.5 microM) was inactive on rabbit vascular strips. Human C5a (2.9-59 nM) decreased spontaneous activity of the rabbit portal vein under resting baseline tension. The C5a relaxed strips of portal vein and pulmonary artery that were precontracted with noradrenaline (NA, 200 nM). On the portal vein, C5a-induced relaxation was preceded by a transient contractile phase which decreased with repeated applications of C5a. The magnitude of C5a-induced relaxation of both vessels increased with repeated stimulation by C5a. Maximal levels of relaxation for the third application of C5a at 59 nM averaged 44% and 17% of the NA-induced contraction plateau in portal vein and pulmonary artery, respectively. Strips of rabbit aorta responded minimally to C5a. Indomethacin (5.6 microM) significantly inhibited C5a-induced relaxation of the portal vein and pulmonary artery but had no effect on the early contractile response of the portal vein. Mepyramine (10 microM) failed to modify the C5a response from either vessel, but it reduced the contractile phase of the C5a response on the portal vein when applied in conjunction with indomethacin. The drug SKF 88046, an end organ antagonist of thromboxane (TX) A2 and some contractile prostaglandins, reduced the contractile phase and increased relaxation of the portal vein to C5a but did not modify the response of the pulmonary artery. Radioimmunoassays for 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) and TXB2 were performed on the fluid bathing rabbit isolated blood vessels. C5a promoted release of 6-keto-PGF1, over the basal release rate in rabbit tissues. Only trace quantities of TXB2 were produced by rabbit vessels exposed to C5a. 7 It is concluded that the mechanical response of blood vessels to C5a is mainly determined by the type of cyclo-oxygenase products released and by the sensitivity of each blood vessel to these active lipids. Tissue histamine release is also responsible for a component of the response of rabbit portal vein to C5a. The relaxant effect of C5a on rabbit blood vessels may be a phenomenon related to the previously reported hypotensive action of classical anaphylatoxins in vivo.
将兔血管条悬于体外,以等张方式记录其对补体肽C3a和C5a的反应。人C3a(浓度高达1.5微摩尔/升)对兔血管条无活性。人C5a(2.9 - 59纳摩尔/升)在静息基线张力下可降低兔门静脉的自发活动。C5a可使预先用去甲肾上腺素(NA,200纳摩尔/升)预收缩的门静脉和肺动脉条舒张。在门静脉上,C5a诱导的舒张之前有一个短暂的收缩期,随着C5a的反复应用,该收缩期减弱。C5a对两种血管诱导的舒张幅度随着C5a的反复刺激而增加。在门静脉和肺动脉中,59纳摩尔/升的C5a第三次应用时的最大舒张水平分别平均为NA诱导收缩平台的44%和17%。兔主动脉条对C5a反应极小。吲哚美辛(5.6微摩尔/升)显著抑制C5a诱导的门静脉和肺动脉舒张,但对门静脉的早期收缩反应无影响。美吡拉敏(10微摩尔/升)未能改变两种血管对C5a的反应,但与吲哚美辛联合应用时,可降低门静脉C5a反应的收缩期。药物SKF 88046是血栓素(TX)A2和一些收缩性前列腺素的终末器官拮抗剂,可降低门静脉对C5a反应的收缩期并增强舒张,但不改变肺动脉的反应。对兔离体血管的浴液进行6 - 酮 - 前列腺素F1α(6 - 酮 - PGF1α)和TXB2的放射免疫测定。C5a促进兔组织中6 - 酮 - PGF1α的释放超过基础释放速率。暴露于C5a的兔血管仅产生微量的TXB2。7得出结论,血管对C5a的机械反应主要由释放的环氧化酶产物类型以及各血管对这些活性脂质的敏感性决定。组织组胺释放也参与兔门静脉对C5a反应的一部分。C5a对兔血管的舒张作用可能是一种与先前报道的经典过敏毒素在体内的降压作用相关的现象。